Inflation Reduction Act Favors Biologics Over Small Molecules: In The Long Term, This Could Partly Undermine Bill’s Effort To Contain Costs

Because the Inflation Reduction Act gives small molecule drugs a shorter, 9-year post-approval window before their “fair prices” are implemented, executives in the pharmaceutical industry have argued that the IRA will “harm innovation,” in particular, with respect to small molecules.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive